Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
作者： Fabrice André , Javier Cortés
DOI: 10.1007/S10549-015-3301-Y
关键词:
摘要: Fibroblast growth factor receptor (FGFR) signaling is involved in multiple biological processes, including cell proliferation, survival, differentiation, migration, and apoptosis during embryonic development adult tissue homeostasis. Given its role the activation of critical pathways, aberrant FGFR has been implicated cancer types. A comprehensive search PubMed congress abstracts was conducted to identify reports on pathway components breast cancer. In cancers, FGFR1 FGFR4 gene amplification single nucleotide polymorphisms FGFR2 have detected. Commonly, these aberrations amplifications lead increased linked with poor prognosis resistance treatments. Here, we review impact genetic amplifications/aberrations tumors. addition, summarize most recent preclinical clinical data FGFR-targeted therapies Finally, highlight ongoing trials agents dovitinib, AZD4547, lucitanib, BGJ398, JNJ-42756493, which are selected for patients pathway-amplified Aberrant may drive some cancers. Inhibition being explored clinic, from refine our ability select who would best respond
springer.com
paperity.org
core.ac.uk参考文章(75)
Daniel E. Johnson, Lewis T. Williams, Structural and Functional Diversity in the FGf Receptor Multigene Family Advances in Cancer Research. ,vol. 60, pp. 1- 41 ,(1992) , 10.1016/S0065-230X(08)60821-0
Robert Zeillinger, Geneviève Louason, Frank Courjal, Paul Speiser, Charles Theillet, Carmen Rodriguez, Joelle Simony-Lafontaine, Marguerite Cuny, Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Research. ,vol. 57, pp. 4360- 4367 ,(1997)
Anne Letessier, Fabrice Sircoulomb, Christophe Ginestier, Nathalie Cervera, Florence Monville, Véronique Gelsi-Boyer, Benjamin Esterni, Jeannine Geneix, Pascal Finetti, Christophe Zemmour, Patrice Viens, Emmanuelle Charafe-Jauffret, Jocelyne Jacquemier, Daniel Birnbaum, Max Chaffanet, Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers BMC Cancer. ,vol. 6, pp. 245- 245 ,(2006) , 10.1186/1471-2407-6-245
Rodrigo Dienstmann, Rastilav Bahleda, Barbara Adamo, Jordi Rodon, Andrea Varga, Anas Gazzah, Suso Platero, Hans Smit, Timothy Perera, Bob Zhong, Kim Stuyckens, Yusri Elsayed, Chris Takimoto, Vijay Peddareddigari, Josep Tabernero, Feng Roger Luo, Jean-Charles Soria, None, Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors Cancer Research. ,vol. 74, ,(2014) , 10.1158/1538-7445.AM2014-CT325
Maria J Garcia, Jessica Pole, Suet-Feung Chin, Andrew Teschendorff, Ali Naderi, Hilal Ozdag, Maria Vias, Tanja Kranjac, Tatiana Subkhankulova, Claire Paish, Ian Ellis, James D Brenton, Paul AW Edwards, Carlos Caldas, None, A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene. ,vol. 24, pp. 5235- 5245 ,(2005) , 10.1038/SJ.ONC.1208741
Christoph Thussbas, Jorg Nahrig, Sylvia Streit, Johannes Bange, Monika Kriner, Ronald Kates, Kurt Ulm, Marion Kiechle, Heinz Hoefler, Axel Ullrich, Nadia Harbeck, FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer Journal of Clinical Oncology. ,vol. 24, pp. 3747- 3755 ,(2006) , 10.1200/JCO.2005.04.8587
A Roidl, P Foo, W Wong, C Mann, S Bechtold, HJ Berger, S Streit, JE Ruhe, S Hart, A Ullrich, HK Ho, None, The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene. ,vol. 29, pp. 1543- 1552 ,(2010) , 10.1038/ONC.2009.432
Koichi Azuma, Junji Tsurutani, Kazuko Sakai, Hiroyasu Kaneda, Yasuhito Fujisaka, Masayuki Takeda, Masahiro Watatani, Tokuzo Arao, Taroh Satoh, Isamu Okamoto, Takayasu Kurata, Kazuto Nishio, Kazuhiko Nakagawa, Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure Biochemical and Biophysical Research Communications. ,vol. 407, pp. 219- 224 ,(2011) , 10.1016/J.BBRC.2011.03.002
Simon N Stacey, Andrei Manolescu, Patrick Sulem, Steinunn Thorlacius, Sigurjon A Gudjonsson, Gudbjörn F Jonsson, Margret Jakobsdottir, Jon T Bergthorsson, Julius Gudmundsson, Katja K Aben, Luc J Strobbe, Dorine W Swinkels, K C Anton van Engelenburg, Brian E Henderson, Laurence N Kolonel, Loic Le Marchand, Esther Millastre, Raquel Andres, Berta Saez, Julio Lambea, Javier Godino, Eduardo Polo, Alejandro Tres, Simone Picelli, Johanna Rantala, Sara Margolin, Thorvaldur Jonsson, Helgi Sigurdsson, Thora Jonsdottir, Jon Hrafnkelsson, Jakob Johannsson, Thorarinn Sveinsson, Gardar Myrdal, Hlynur Niels Grimsson, Steinunn G Sveinsdottir, Kristin Alexiusdottir, Jona Saemundsdottir, Asgeir Sigurdsson, Jelena Kostic, Larus Gudmundsson, Kristleifur Kristjansson, Gisli Masson, James D Fackenthal, Clement Adebamowo, Temidayo Ogundiran, Olufunmilayo I Olopade, Christopher A Haiman, Annika Lindblom, Jose I Mayordomo, Lambertus A Kiemeney, Jeffrey R Gulcher, Thorunn Rafnar, Unnur Thorsteinsdottir, Oskar T Johannsson, Augustine Kong, Kari Stefansson, Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nature Genetics. ,vol. 40, pp. 703- 706 ,(2008) , 10.1038/NG.131
Ailin Bai, Kristan Meetze, Nhi Y Vo, Sriram Kollipara, Elizabeth K Mazsa, William M Winston, Solly Weiler, Laura L Poling, Ting Chen, Nesreen S Ismail, Jinwei Jiang, Lorena Lerner, Jeno Gyuris, Zhigang Weng, None, GP369, an FGFR2-IIIb specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling Cancer Research. ,vol. 70, pp. 7630- 7639 ,(2010) , 10.1158/0008-5472.CAN-10-1489